Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: Mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A

BMC Bioinformatics

Volumn 12, Issue SUPPL. 13, 2011, Pages

  Grover, Abhinav ^a   Agrawal, Vibhuti ^a   Shandilya, Ashutosh ^a   Bisaria, Virendra S ^a   Sundar, Durai ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACTION MECHANISMS; BINDING AFFINITIES; BINDING CONFORMATIONS; BINDING MECHANISMS; BIOLOGICAL WARFARE AGENTS; DNA POLYMERASE; DOCKING ALGORITHMS; DOCKING SIMULATIONS; DYNAMIC BEHAVIOURS; HERBAL DRUG; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HIGH SPECIFICITY; KEY RESIDUES; MD SIMULATION; MODE OF ACTION; MOLECULAR DYNAMICS SIMULATIONS; NATURALLY OCCURRING; NON-SPECIFICITY; NUCLEOSIDE ANALOGUES; POTENT ACTIVITY; POTENTIAL LIGAND; RECEPTOR-LIGAND INTERACTIONS; SELECTIVE INHIBITORS; THERAPEUTIC ARSENAL; VIRAL DNA;

BINDING ENERGY; CONFORMATIONS; DNA; LIGANDS; MOLECULAR DYNAMICS; VIRUSES;

POLYMERS;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

ANTIVIRUS AGENT; DNA DIRECTED DNA POLYMERASE; DNA POLYMERASE, SIMPLEXVIRUS; EXODEOXYRIBONUCLEASE; VIRUS DNA; VIRUS PROTEIN; WITHAFERIN A; WITHANOLIDE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HERPES SIMPLEX; HERPES VIRUS INFECTION; HUMAN; MOLECULAR DYNAMICS; PROSPECTIVE STUDY; SIMPLEXVIRUS;

ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; EXODEOXYRIBONUCLEASES; HERPES SIMPLEX; HERPESVIRIDAE INFECTIONS; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROSPECTIVE STUDIES; SIMPLEXVIRUS; VIRAL PROTEINS; WITHANOLIDES;

EID: 84864067111     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-12-S13-S22     Document Type: Article

References (37)

1. Prevention and control of Herpes virus diseases. Clinical and laboratory diagnosis and chemotherapy 1985, 63:182-185. Bulletin of the WHO.
2. Whitley RJ, Gnann JWJ. The Human Herpesviruses. The Human Herpesviruses 1993, 69-105. Roizmann B, Whitley RJ, Lopez C.
3. Wild K, Bohner T, Folkers G, Schulz GE. The structures of thymidine kinase from Herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Science 1997, 6:2097-2106. 2143568, 9336833.
4. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM, Paavonen J, Morrow RA, Beutner KR, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. New England Journal of Medicine 2004, 350:11-20. 10.1056/NEJMoa035144, 14702423.
5. Siakallis G, Spandidos DA, Sourvinos G. Herpesviridae and novel inhibitors. Antiviral Therapy 2009, 14:1051-1064.
6. Coen DM, Schaffer PA. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat Rev Drug Discov 2003, 2:278-288. 10.1038/nrd1065, 12669027.
7. Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with Herpes-simplex virus in a patient with Acquired Immunodeficiency Syndrome. New England Journal of Medicine 1989, 320:297-300. 10.1056/NEJM198902023200507, 2536137.
8. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalo-virus in immunocompromised patients. New England Journal of Medicine 1989, 320:289-293. 10.1056/NEJM198902023200505, 2536135.
9. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM, Crumpacker CS. Acyclovir-Resistant Herpes-Simplex Virus-Infections in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine 1989, 320:293-296. 10.1056/NEJM198902023200506, 2536136.
10. Field AK, Biron KK. The end of innocence revisited - resistance of Herpesviruses to antiviral drugs. Clinical Microbiology Reviews 1994, 7:1-13. 358302, 8118786.
11. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002, 5:88-114. 10.1016/S1368-7646(02)00021-3, 12135584.
12. Hirsch MS, Schooley RT. Resistance to antiviral drugs: the end of innocence. N Engl J Med 1989, 320:313-314. 10.1056/NEJM198902023200510, 2536138.
13. Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993, 329:1777-1782. 10.1056/NEJM199312093292405, 8232486.
14. Greco A, Diaz JJ, Thouvenot D, Morfin F. Novel targets for the development of anti-herpes compounds. Infect Disord Drug Targets 2007, 7:11-18. 10.2174/187152607780090766, 17346207.
15. Liu S, Knafels JD, Chang JS, Waszak GA, Baldwin ET, Deibel MR, Thomsen DR, Homa FL, Wells PA, Tory MC, et al. Crystal structure of the herpes simplex virus 1 DNA polymerase. Journal of Biological Chemistry 2006, 281:18193-18200. 10.1074/jbc.M602414200, 16638752.
16. Kambizi L, Goosen BM, Taylor MB, Afolayan AJ. Anti-viral effects of aqueous extracts of Aloe ferox and Withania somnifera on herpes simplex virus type 1 in cell culture. South African Journal of Science 2007, 103:359-360.
17. Verma H, Patil PR, Kolhapure RM, Gopalkrishna V. Antiviral activity of the Indian medicinal plant extract, Swertia chirata against herpes simplex viruses: A study by in-vitro and molecular approach. Indian Journal of Medical Microbiology 2008, 26:322-326. 10.4103/0255-0857.43561, 18974483.
18. Widodo N, Takagi Y, Shrestha BG, Ishii T, Kaul SC, Wadhwa R. Selective killing of cancer cells by leaf extract of Ashwagandha: Components, activity and pathway analyses. Cancer Letters 2008, 262:37-47. 10.1016/j.canlet.2007.11.037, 18191020.
19. Mishra L, Singh B, Dagenias S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Alternative Medicine Review 2000, 5:334-336.
20. Panda S, Kar A. Changes in thyroid hormone concentrations after administration of Ashwagandha root extract to adult male mice. Journal of Pharmacy and Pharmacology 1998, 50:1065-1068. 10.1111/j.2042-7158.1998.tb06923.x, 9811169.
21. Budhiraja RD, Sudhir S. Review of Biological-Activity of Withanolides. Journal of Scientific & Industrial Research 1987, 46:488-491. 3195820, 22025968.
22. Kulkarni S, George B, Mathur R. Protective effect of Withania somnifera root extract on electrographic activity in a lithium pilocarpine model of status epilepticus. Phytotherapy Research 1998, 12:451-453.
23. Bhattacharya A, Ghosal S, Bhattacharya SK. Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. Journal of Ethnopharmacology 2001, 74:1-6. 10.1016/S0378-8741(00)00309-3, 11137343.
24. Bhattacharya SK, Muruganandam AV. Adaptogenic activity of Withania somnifera: an experimental study using a rat model of chronic stress. Pharmacology Biochemistry and Behavior 2003, 75:547-555.
25. Chaudhary G, Sharma U, Jagannathan NR, Gupta YK. Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clinical and Experimental Pharmacology and Physiology 2003, 30:399-404. 10.1046/j.1440-1681.2003.03849.x, 12859433.
26. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazon J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules 2009, 14:2373-2393. 10.3390/molecules14072373, 19633611.
27. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Research 2000, 28:235-242. 10.1093/nar/28.1.235, 102472, 10592235.
28. Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, Sundar D. Hsp90/Cdc37 Chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics 2011, 12(Suppl 1):S30. 10.1186/1471-2105-12-S1-S30, 3044286, 21342561.
29. NCBI-PubChem Compound database. , http://pubchem.ncbi.nlm.nih.gov/
30. Case DA DT, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Walker RC, Zhang W, Merz KM, Roberts B, Wang B, Hayik S, Roitberg A, Seabra G, Kolossváry I, Wong IF, Paesani F, Vanicek J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Cai Q, Ye X, Wang J, Hsieh MJ, Cui G, Roe DR, Mathews DH, Seetin MG, Sagui C, Babin V, Luchko T, Gusarov S, Kovalenko A, Kollman PA. AMBER 11. 2010, San Francisco: University of California.
31. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 1998, 19:1639-1662.
32. DeLano W. The PyMOL Molecular Graphics System 2002. 2002, San Carlos, CA: DeLano Scientific.
33. Jain T, Jayaram B. An all atom energy based computational protocol for predicting binding affinities of protein-ligand complexes. Febs Letters 2005, 579:6659-6666. 10.1016/j.febslet.2005.10.031, 16307743.
34. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995, 8:127-134. 10.1093/protein/8.2.127, 7630882.
35. Brideau RJ, Knechtel ML, Huang A, Vaillancourt VA, Vera EE, Oien NL, Hopkins TA, Wieber JL, Wilkinson KF, Rush BD, et al. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res 2002, 54:19-28. 10.1016/S0166-3542(01)00208-X, 11888654.
36. Oien NL, Brideau RJ, Hopkins TA, Wieber JL, Knechtel ML, Shelly JA, Anstadt RA, Wells PA, Poorman RA, Huang A, et al. Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob Agents Chemother 2002, 46:724-730. 10.1128/AAC.46.3.724-730.2002, 127502, 11850254.
37. Vajpayee M, Malhotra N. Antiviral drugs against herpes infection. Indian Journal of Pharmacology 2000, 32:330-338.